FrancophonIA/ELRC3.0 huggingface dataset:
English: Additionally, when added on to background metformin and sitagliptin therapy, ertugliflozin 5 mg and 15 mg resulted in statistically significant placebo subtracted reductions in SBP of 2.9 and 3.9 mmHg, respectively.
Danish: Det medførte desuden statistisk signifikante placebosubtraherede fald i systolisk blodtryk på henholdsvis 2,9 og 3,9 mmHg, når ertugliflozin 5 mg og 15 mg blev givet i tillæg til baggrundsbehandling med metformin og behandling med sitagliptin.
English: After 26-weeks of treatment, the combination of ertugliflozin 5 mg or 15 mg and sitagliptin 100 mg resulted in statistically significant reductions in systolic blood pressure (SBP) compared to sitagliptin alone (-2.8 and -3.0 mmHg for E5/S100 and E15/S100 respectively) or placebo (-4.4 and -6.4 mmHg for E5/S100 and E15/S100, respectively).
Danish: (henholdsvis -2,8 og -3,0 mmHg for E5/S100 og E15/S100) eller placebo (henholdsvis -4,4 og -6,4 mmHg for E5/S100 og E15/S100).
English: Arthralgia a,2
Danish: Artralgi a,2
English: How to take Steglujan
Danish: Sådan skal du tage Steglujan
English: Uncommon Not known Not known Not known Not known
Danish: Ikke almindelig Ikke kendt Ikke kendt Ikke kendt Ikke kendt
English: Steglujan 5 mg/100 mg film-coated tablets Steglujan 15 mg/100 mg film-coated tablets
Danish: Steglujan 5 mg/100 mg filmovertrukne tabletter Steglujan 15 mg/100 mg filmovertrukne tabletter
English: In a pre-/post-natal development study performed in rats sitagliptin showed no adverse effects.
Danish: Sitagliptin viste ingen bivirkninger i et præ- og postnatalt udviklingsstudie udført med rotter.
English: Steglujan 15 mg/100 mg film-coated tablets
Danish: Steglujan 15 mg/100 mg filmovertrukne tabletter
English: Rash a,
Danish: Udslæt a,
English: • Steglujan 15 mg/100 mg film-coated tablets (tablets) are brown, 12.0 x 7.4 mm, almond-shaped,
Danish: • Steglujan 15 mg/100 mg filmovertrukne tabletter (tabletter) er brune, 12,0 x 7,4 mm, mandelformede, filmovertrukne tabletter med “555” præget på den ene side og uden prægning på den anden side.
English: Not known Not known Not known Not known
Danish: Ikke kendt Ikke kendt Ikke kendt Ikke kendt
English: BLISTER FOR STEGLUJAN 15 mg/100 mg
Danish: BLISTER TIL STEGLUJAN 15 mg/100 mg
English: BLISTER FOR STEGLUJAN 5 mg/100 mg
Danish: BLISTER TIL STEGLUJAN 5 mg/100 mg
English: • osteoarthritis
Danish: • mavesmerter
English: Steglujan 5 mg/100 mg film-coated tablets
Danish: Steglujan 5 mg/100 mg filmovertrukne tabletter
English: Steglujan should not be initiated in patients with an eGFR below 60 ml/min/1.73 m 2 or CrCl below 60 ml/min.
Danish: Behandling med Steglujan må ikke initieres hos patienter med eGFR under 60 ml/min/1,73 m 2 eller
English: CARTON FOR STEGLUJAN 15 mg/100 mg
Danish: KARTON TIL STEGLUJAN 15 mg/100 mg
English: CARTON FOR STEGLUJAN 5 mg/100 mg
Danish: KARTON TIL STEGLUJAN 5 mg/100 mg
English: Steglujan 5 mg/100 mg film-coated tablets Steglujan 15 mg/100 mg film-coated tablets ertugliflozin/sitagliptin
Danish: Steglujan 5 mg/100 mg filmovertrukne tabletter Steglujan 15 mg/100 mg filmovertrukne tabletter ertugliflozin/sitagliptin
English: Steglujan 15 mg/100 mg tablets ertugliflozin/sitagliptin
Danish: Steglujan 15 mg/100 mg tabletter ertugliflozin/sitagliptin
English: • flatulence
Danish: • svedtendens
English: In clinical studies, sitagliptin did not meaningfully alter the pharmacokinetics of metformin, glyburide, simvastatin, rosiglitazone, warfarin, or oral contraceptives, providing in vivo evidence of a low propensity for causing interactions with substrates of CYP3A4, CYP2C8, CYP2C9, and OCT. Sitagliptin may be a mild inhibitor of P-gp in vivo.
Danish: Dette giver in vivo-evidens for lav tilbøjelighed til at forårsage interaktion med substrater for CYP3A4, CYP2C8, CYP2C9, og OCT. Sitagliptin kan være en svag hæmmer af P-gp in vivo.
English: Uncommon Not known Not known Not known
Danish: Ikke almindelig Ikke kendt Ikke kendt Ikke kendt
English: Steglujan 5 mg/100 mg tablets ertugliflozin/sitagliptin
Danish: Steglujan 5 mg/100 mg tabletter ertugliflozin/sitagliptin
English: increased
Danish: Virkning
English: Each tablet contains 5 mg of ertugliflozin (as ertugliflozin L-pyroglutamic acid) and 100 mg of sitagliptin (as sitagliptin phosphate monohydrate).
Danish: Hver tablet indeholder 5 mg ertugliflozin (som ertugliflozin L-pyroglutaminsyre) og 100 mg sitagliptin (som sitagliptinphosphatmonohydrat).
English: Each tablet contains 15 mg of ertugliflozin (as ertugliflozin L-pyroglutamic acid) and 100 mg of sitagliptin (as sitagliptin phosphate monohydrate).
Danish: Hver tablet indeholder 15 mg ertugliflozin (som ertugliflozin L-pyroglutaminsyre) og 100 mg sitagliptin (som sitagliptinphosphatmonohydrat).
English: o Each Steglujan 15 mg/100 mg film-coated tablet contains 15 mg of ertugliflozin (as ertugliflozin L-pyroglutamic acid) and 100 mg sitagliptin (as sitagliptin phosphate monohydrate).
Danish: o Hver Steglujan 15 mg/100 mg filmovertrukken tablet indeholder 15 mg ertugliflozin (som ertugliflozin L-pyroglutaminsyre) og 100 mg sitagliptin (som sitagliptinphosphatmonohydrat).
English: o Each Steglujan 5 mg/100 mg film-coated tablet contains 5 mg of ertugliflozin (as ertugliflozin L-pyroglutamic acid) and 100 mg sitagliptin (as sitagliptin phosphate monohydrate).
Danish: o Hver Steglujan 5 mg/100 mg filmovertrukken tablet indeholder 5 mg ertugliflozin (som ertugliflozin L-pyroglutaminsyre) og 100 mg sitagliptin (som sitagliptinphosphatmonohydrat).
English: Luxembourg/Luxemburg MSD Belgium BVBA/SPRL Tél/Tel: +32(0)27766211 dpoc_belux@merck.com
Danish: Tél/Tel: +32(0)27766211 dpoc_belux@merck.com
English: In patients where DKA is suspected or diagnosed, treatment with Steglujan should be discontinued immediately.
Danish: Behandlingen med Steglujan straks seponeres hos patienter med formodet eller diagnosticeret diabetisk ketoacidose.
English: Steglujan 15 mg/100 mg film-coated tablets ertugliflozin/sitagliptin
Danish: Steglujan 15 mg/100 mg filmovertrukne tabletter ertugliflozin/sitagliptin
English: • feeling sick or being sick
Danish: • stoppet næse eller snue og ondt i halsen
English: Steglujan 5 mg/100 mg film-coated tablets ertugliflozin/sitagliptin
Danish: Steglujan 5 mg/100 mg filmovertrukne tabletter ertugliflozin/sitagliptin
English: Elderly patients are more likely to have decreased renal function.
Danish: Dosisjustering af Steglujan anbefales ikke på basis af alder. Der er større sandsynlighed for, at ældre patienter har nedsat nyrefunktion.
English: Constipation Vomiting a,2
Danish: Obstipation Opkastning a,2
English: Kriptazen received a marketing authorisation valid throughout the EU on 8 February 2019.
Danish: Kriptazen fik en markedsføringstilladelse med gyldighed i hele EU den 8. februar 2019.
English: It is given to newborn calves once a day for one week.
Danish: Det gives til nyfødte kalve en gang dagligt i en uge.
English: Kriptazen should be given after feeding.
Danish: Kriptazen bør gives efter fodring.
English: Kriptazen (halofuginone)
Danish: Kriptazen (halofuginon)
English: Other information about Kriptazen
Danish: Andre oplysninger om Kriptazen
English: Further information on Kriptazen can be found on the Agency's website: ema.europa.eu/medicines/veterinary/EPAR/Kriptazen.
Danish: Yderligere information om Kriptazen findes på agenturets websted under: ema.europa.eu/medicines/veterinary/EPAR/Kriptazen.
English: What are the benefits and risks of Kriptazen?
Danish: Hvilke fordele og risici er der forbundet med Kriptazen?
English: The withdrawal period for meat from newborn calves treated with Kriptazen is 13 days.
Danish: Tilbageholdelsestiden for kød fra nyfødte kalve, der er behandlet med Kriptazen, er 13 dage.
English: Kriptazen (halofuginone) EMA/878973/2018
Danish: Kriptazen (halofuginon) EMA/878973/2018
English: An overview of Kriptazen and why it is authorised in the EU
Danish: En oversigt over Kriptazen, og hvorfor det er godkendt i EU
English: What is Kriptazen and what is it used for?
Danish: Hvad er Kriptazen, og hvad anvendes det til?
English: every medicine, the company provided studies on the quality and manufacture of Kriptazen.
Danish: Som for alle lægemidler fremlagde virksomheden studier vedrørende kvaliteten og fremstillingen af Kriptazen.
English: The European Medicines Agency concluded that, in accordance with EU requirements, Kriptazen has been shown to be comparable to Halocur.
Danish: Det Europæiske Lægemiddelagentur konkluderede, at det i overensstemmelse med EU's krav er påvist, at Kriptazen er sammenligneligt med Halocur.
English: No additional studies were needed as Kriptazen is a water based oral solution containing the same active substance and other ingredients as the reference medicine.
Danish: Der var ikke behov for yderligere studier, da Kriptazen er en vandbaseret oral opløsning, der indeholder det samme aktive stof og øvrige indholdsstoffer som referencelægemidlet.
English: Why is Kriptazen authorised in the EU?
Danish: Hvorfor blev Kriptazen godkendt i EU?
English: Studies on the benefits and risks of the active substance in the authorised use have already been carried out with the reference medicine, Halocur, and do not need to be repeated for Kriptazen.
Danish: Der er allerede foretaget studier over det aktive stofs fordele og risici ved godkendt brug med referencelægemidlet, Halocur, og de behøver ikke blive gentaget for Kriptazen.
English: Because Kriptazen is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.
Danish: Da Kriptazen er et generisk lægemiddel, anses dets fordele og risici for at være de samme som for referencelægemidlet.
English: This means that Kriptazen contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the European Union (EU) called Halocur.
Danish: Det betyder, at Kriptazen indeholder det samme aktive stof og virker på samme måde som et "referencelægemiddel", som allerede er godkendt i Den Europæiske Union (EU), og som hedder Halocur.
English: The precautions are the same as for the reference medicine since Kriptazen is a generic medicine.
Danish: Disse forholdsregler er de samme som for referencelægemidlet, eftersom Kriptazen er et generisk lægemiddel.
English: It also limits the spread of the disease by preventing the formation of oocysts, which are a stage in the lifecycle of the parasite where it is infectious and which are passed in the faeces.
Danish: Det begrænser også spredningen af sygdommen ved at forebygge dannelse af oocyster, som er en fase i parasittens livscyklus, hvor den er smitsom, og som udskilles i afføringen.
English: Kriptazen contains the active substance halofuginone and is a ‘generic medicine'.
Danish: Kriptazen indeholder det aktive stof halofuginon og er et "generisk lægemiddel".
English: The exact way halofuginone works is unknown.
Danish: Det vides ikke nøjagtigt, hvordan halofuginon virker.
English: For prevention of diarrhoea, treatment should start within 24 to 48 hours of birth; for reducing diarrhoea, treatment should start within 24 hours of the start of the diarrhoea.
Danish: Til forebyggelse af diarré bør behandlingen påbegyndes inden for 24 til 48 timer efter fødslen.
English: For more information about using Kriptazen, see the package leaflet or contact your veterinarian or pharmacist.
Danish: Hvis du ønsker flere oplysninger om anvendelsen af Kriptazen, kan du læse indlægssedlen eller kontakte din dyrlæge eller dit apotek.
English: Safety information has been included in the summary of product characteristics and the package leaflet for Kriptazen, including the appropriate precautions to be followed by healthcare professionals and animal owners or keepers.
Danish: Der er anført sikkerhedsoplysninger i produktresuméet og indlægssedlen for Kriptazen, herunder passende forholdsregler, som skal følges af sundhedspersoner og den, der er ejer af eller ansvarlig for dyret.
English: Kriptazen can only be obtained with a prescription and is available as an oral solution (liquid to be given by mouth).
Danish: Kriptazen udleveres kun efter recept og fås som oral opløsning (væske, som indgives gennem munden).
English: Kriptazen is a medicine used to treat newborn calves to prevent or reduce diarrhoea caused by an organism called Cryptosporidium parvum.
Danish: Kriptazen er et lægemiddel, som anvendes hos nyfødte kalve til forebyggelse eller reduktion af diarré forårsaget af en organisme kaldet Cryptosporidium parvum.
English: Therefore, the Agency's view was that, as for Halocur, the benefit of Kriptazen outweighs the identified risk and it can be authorised for use in the EU.
Danish: Det var derfor agenturets opfattelse, at fordelene ved Kriptazen opvejer de identificerede risici som for Halocur, og at det kan godkendes til anvendelse i EU.
English: The active substance in Kriptazen, halofuginone lactate, prevents the growth of Cryptosporidium parvum.
Danish: Det aktive stof i Kriptazen, halofuginonlactat, forhindrer væksten af Cryptosporidium parvum.
English: This is a parasite belonging to the ‘protozoa' family that invades the digestive system, producing an infection called cryptosporidiosis that results in diarrhoea.
Danish: Det er en parasit, som tilhører familien "protozoer", der invaderer fordøjelsessystemet og medfører en infektion kaldet cryptosporidiose, som giver diarré.
English: How has Kriptazen been studied?
Danish: Hvordan er Kriptazen blevet undersøgt?
English: How is Kriptazen used?
Danish: Hvordan anvendes Kriptazen?
English: How does Kriptazen work?
Danish: Hvordan virker Kriptazen?
English: The European Commission issued a decision on 22 March 2016.
Danish: Europa-Kommissionen traf en afgørelse den 22. marts 2016.
English: Outcome of a procedure under Article 78 of Directive 2001/82/EC
Danish: Resultatet af en procedure i henhold til artikel 78 i direktiv 2001/82/EF
English: 1 Austria, Belgium, Czech Republic, Denmark, France, Germany, Greece, Ireland, Italy, Poland, Portugal, Romania, Spain, Sweden, Slovenia, Slovakia and the United Kingdom
Danish: 1 Østrig, Belgien, Tjekkiet, Danmark, Frankrig, Tyskland, Grækenland, Irland, Italien, Polen, Portugal, Rumænien, Spanien, Sverige, Slovenien, Slovakiet og Det Forenede Kongerige
English: Accordingly, the CVMP was requested to give its opinion on the matter concerning animal safety.
Danish: Derfor blev CVMP anmodet om at afgive en udtalelse i sagen, hvad angår dyrenes sikkerhed.
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom22 March 2016
Danish: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom22.
English: It was also recommended that the suspension of the marketing authorisation for CLOSAMECTIN POURON SOLUTION POUR BOVINS in France be lifted.
Danish: Det anbefales også, at suspenderingen af markedsføringstilladelsen for CLOSAMECTIN POUR-ON SOLUTION POUR BOVINS i Frankrig ophæves.
English: Although the overall incidence of adverse events was considered to be within acceptable limits (0.006% in the last annual periodic safety update report ) the continued occurrence of serious adverse events and the severity of subsequent losses on farms in France were considered significant, which led to the suspension of the marketing authorisation in France on 6 July 2015.
Danish: Skønt den samlede forekomst af bivirkninger blev anset for at være inden for det acceptable (0,006 % i den seneste årlige periodiske opdaterede sikkerhedsindberetning), blev den fortsatte forekomst af alvorlige bivirkninger med efterfølgende alvorlige tab på brug i Frankrig anset for at være betydningsfuld, hvilket førte til suspendering af markedsføringstilladelsen i Frankrig den 6. juli 2015.
English: Questions and answers on Closamectin Pour-On Solution and associated names EMA/672999/2015
Danish: Spørgsmål og svar om Closamectin Pour-On, opløsning, og relaterede navne EMA/672999/2015
English: • conditions of the marketing authorisations concerning risk mitigation and surveillance measures.
Danish: • at der fastsættes betingelser for markedsføringstilladelserne, hvad angår risikominimerings- og overvågningsforanstaltninger.
English: Between 25 May 2011 and 31 May 2015 the French medicines regulatory agency (Agence Nationale du Médicament Vétérinaire (ANMV)) received a total of 123 adverse event reports involving CLOSAMECTIN POUR-ON POUR BOVINS in which 401 animals were affected and 121 died.
Danish: Fra den 25. maj 2011 til den 31. maj 2015 modtog den franske lægemiddelmyndighed (Agence Nationale du Médicament Vétérinaire (ANMV)) i alt 123 indberetninger om bivirkninger relateret til CLOSAMECTIN POUR-ON POUR BOVINS, der berørte 401 dyr, hvoraf 121 døde.
English: Closamectin Pour-On Solution and associated names contain closantel and ivermectin and are authorised in several European Union (EU) Member States1 via decentralised and national procedures.
Danish: Closamectin Pour-On, opløsning, og relaterede navne indeholder closantel og ivermectin og er godkendt i flere EU-medlemsstater1 via decentraliserede og nationale procedurer.
English: On 19 June 2015, France triggered a procedure under Article 78 of Directive 2001/82/EC for Closamectin Pour-On Solution and associated names following evaluation of pharmacovigilance data indicating serious concerns for animal safety and subsequent suspension of the marketing authorisation for the product.
Danish: Den 19. juni 2015 indledte Frankrig en procedure i henhold til artikel 78 i direktiv 2001/82/EF vedrørende Closamectin Pour-On, opløsning, og relaterede navne efter vurdering af lægemiddelovervågningsdataene, der gav anledning til alvorlig bekymring for dyrenes sikkerhed, hvorefter markedsføringstilladelsen for produktet blev suspenderet.
English: Questions and answers on Closamectin Pour-On Solution and associated names
Danish: Spørgsmål og svar om Closamectin Pour-On, opløsning, og relaterede navne
English: On 8 October 2015, the European Medicines Agency (the Agency) completed a review of the animal safety of Closamectin Pour-On Solution and associated names.
Danish: Den 8. oktober 2015 afsluttede Det Europæiske Lægemiddelagentur (agenturet) en gennemgang af sikkerheden ved veterinærlægemidlet Closamectin Pour-On, opløsning, og relaterede navne.
English: This included a review of scientific literature regarding the pharmacology and toxicology of ivermectin and closantel, cumulative pharmacovigilance experience following use of the products in the EU since 2009, a comparison with ivermectin-based products and with ivermectin/closantel injectable formulations held by the MAH, investigations carried out by the MAH to identify possible factors involved in reported adverse events and proposals for risk mitigation measures and actions.
Danish: Dette omfattede en gennemgang af den videnskabelige litteratur om ivermectins og closantels farmakologi og toksikologi, de kumulative lægemiddelovervågningserfaringer efter anvendelsen af produkterne i EU siden 2009, en sammenligning med ivermectin-baserede produkter og injicerbare ivermectin/closantel-formuleringer, som indehaveren af markedsføringstilladelsen har rettighederne til, undersøgelser udført af indehaveren af markedsføringstilladelsen til identifikation af faktorer, der kan have betydning for de indberettede bivirkninger, samt forslag til risikominimeringsforanstaltninger og -tiltag.
English: What is Closamectin Pour-On Solution and associated names?
Danish: Hvad er Closamectin Pour-On, opløsning, og relaterede navne?
English: Based on the evaluation of the currently available data and the scientific discussion within the Committee, the CVMP concluded that the benefits of Closamectin Pour-On Solution and associated names continue to outweigh their risks subject to:
Danish: Efter vurdering af de foreliggende data og den videnskabelige drøftelse i udvalget konkluderede CVMP, at fordelene ved Closamectin Pour-On, opløsning, og relaterede navne stadig er større end risiciene, forudsat:
English: To investigate the potential relation between the adverse events observed and Closamectin Pour-On Solution and associated names, the CVMP considered the data provided by the marketing authorisation holder (MAH).
Danish: For at undersøge den mulige sammenhæng mellem de observerede bivirkninger og Closamectin PourOn, opløsning, og relaterede navne gennemgik CVMP dataene fra indehaveren af markedsføringstilladelsen.
English: The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Closamectin Pour-On Solution and associated names continue to outweigh their risks subject to variation of the marketing authorisations to include new adverse reactions and precautionary measures and conditions concerning risk mitigation and surveillance measures.
Danish: Agenturets Udvalg for Lægemidler til Dyr (CVMP) konkluderede, at fordelene ved Closamectin Pour-On, opløsning, og relaterede navne stadig opvejer risiciene, forudsat at der foretages ændringer i markedsføringstilladelserne, så de omfatter nye bivirkninger samt forholdsregler og betingelser, hvad angår risikominimerings- og overvågningsforanstaltninger.
English: • variation of the marketing authorisations for Closamectin Pour-On Solution and associated names to amend the summary of product characteristics and package leaflet to include new precautionary measures and adverse reactions; and
Danish: • at der foretages ændringer i markedsføringstilladelserne for Closamectin Pour-On, opløsning, og relaterede navne, så produktresuméet og indlægssedlen omfatter nye forholdsregler og bivirkninger, og
English: Why were Closamectin Pour-On Solution and associated names reviewed?
Danish: Hvorfor blev Closamectin Pour-On, opløsning, undersøgt?
English: The possibility of sensitisation should be taken into account.
Danish: Risikoen for overfølsomhed bør tages i betragtning.
English: Not known (cannot be estimated from the available data)
Danish: Ikke kendt (kan ikke fastslås ud fra forhåndenværende data)
English: These are usually reversible.
Danish: Disse symptomer er sædvanligvis reversible.
English: PK/PD relationship
Danish: PK/PD forhold
English: After the Commission Decision the Member State Competent Authorities, in liaison with the Reference Member State, will update the product information as required.
Danish: Efter commissionen afgørelse skal de enkeltes medlemslandes myndigheder i samarbejde med Reference landet opdaterer produktinformationen som krævet.
English: Symptoms and signs of overdose
Danish: Symptomer og tegn på overdosering
English: The duration of therapy should be determined by the response of the patient.
Danish: Behandlingsvarigheden bør fastlægges i henhold til patientens respons.
English: {Name and address} <{Tel}> <{Fax}> <{e-mail}>
Danish: {Navn og adresse} <{tlf}> <{fax}> <{email}>
English: Urinary recovery (%, 0 to 6 h )
Danish: Opsamlet urin (%, 0 til 6 timer)
English: Augmentin sustained release formulation has a unique PK/PD profile.
Danish: Augmentin vedvarende udløsning formulering har en unik PK/PD profil.
English: • Acute otitis media
Danish: • Akut otitis media
English: Therefore, this SPC, labelling and package leaflet may not necessarily represent the current text
Danish: Derfor repræsenterer dette SPC, mærkning og indlægsseddel ikke nødvendigvis den gældende tekst.
English: 3 At the site of injection
Danish: 3 På injektionsstedet
English: Both halves of each tablet must be taken at the same time.
Danish: Begge halvdele af tabletten skal tages på samme tid.
English: Administration should be by intravenous infusion.
Danish: Administration bør foregå ved intravenøs infusion.
English: To stop infections during and after surgery
Danish: Forhindre infektion før og efter operation
English: Oral anticoagulants and penicillin antibiotics have been widely used in practice without reports of interaction.
Danish: Orale antikoagulantia og penicilliner har været brugt i stort omfang i praksis uden rapportering af interaktioner.
English: • blood takes longer to clot
Danish: • Blodet er længere tid om at størkne
English: Do not take 2 doses in 1 hour.
Danish: De må ikke tage 2 doser inden for 1 time.
English: <{Tel}> <{Fax}> <{e-mail}>
Danish: <{fax}> <{email}>